Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Short term Debt (2020 - 2022)

Anika Therapeutics has reported Short term Debt over the past 7 years, most recently at $4.3 million for Q2 2022.

  • Quarterly Short term Debt fell 74.42% to $4.3 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Jun 2022, down 74.42% year-over-year, with the annual reading at $4.3 million for FY2021, 67.04% down from the prior year.
  • Short term Debt was $4.3 million for Q2 2022 at Anika Therapeutics, roughly flat from $4.3 million in the prior quarter.
  • Over five years, Short term Debt peaked at $24.8 million in Q1 2021 and troughed at $4.3 million in Q3 2021.
  • The 3-year median for Short term Debt is $4.3 million (2021), against an average of $10.3 million.
  • Year-over-year, Short term Debt crashed 67.04% in 2021 and then crashed 82.68% in 2022.
  • A 3-year view of Short term Debt shows it stood at $13.1 million in 2020, then plummeted by 67.04% to $4.3 million in 2021, then changed by 0.0% to $4.3 million in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Short term Debt are $4.3 million (Q2 2022), $4.3 million (Q1 2022), and $4.3 million (Q4 2021).